Study S002227

Safety and Effect of Liraglutide in Patients With Type 2 Diabetes and Severe Renal Insufficiency

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01394341
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: COMPLETED
Enrollment: 40
Start: 2011-09
Primary completion: 2013-10
Lead sponsor: Bo Feldt-Rasmussen
Conditions: Type 2 Diabetes Mellitus; End-stage Renal Disease
Interventions: DRUG:Liraglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2010-021922-36

Registered primary outcomes

Plasma liraglutide concentration (pmol/L) [12 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010237	Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews	2025	Systematic review	PMID 39963952 DOI	cites ClinicalTrials.gov:NCT01394341; registry reference DERIVED:39963952
R0026106	Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Idorn T, Diabetes care	2016	Randomized trial	PMID 26283739 DOI	cites ClinicalTrials.gov:NCT01394341; registry reference DERIVED:26283739
R0017067	Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. Idorn T, BMJ open	2013	Protocol	PMID 23624993 DOI	cites ClinicalTrials.gov:NCT01394341; registry reference DERIVED:23624993